• DiscoveryProbe™ FDA-approved Drug Library: Structure, Evi...

  2025-10-26

  The DiscoveryProbe™ FDA-approved Drug Library (L1021) is a validated collection of 2,320 clinically approved bioactive compounds for high-throughput and high-content drug screening. This resource enables rigorous pharmacological target identification and accelerates drug repositioning across oncology, neurodegeneration, and other disease areas.

• Filipin III: Transforming Cholesterol Detection and Membr...

  2025-10-25

  This thought-leadership article examines how Filipin III, a cholesterol-binding fluorescent antibiotic, is revolutionizing membrane cholesterol visualization and lipidomics in disease models. Grounded in mechanistic insight and current breakthroughs in metabolic liver disease, the article offers strategic guidance for translational researchers aiming to decode cholesterol-driven pathophysiology and accelerate precision therapeutic discovery.

• Filipin III: Precision Cholesterol Detection in Membrane ...

  2025-10-24

  Filipin III, a cholesterol-binding fluorescent antibiotic, revolutionizes membrane cholesterol visualization and lipid raft research with high specificity and advanced imaging compatibility. This guide details optimized workflows, advanced applications, and expert troubleshooting, empowering researchers to dissect cholesterol-related membrane dynamics in disease models and beyond.

• Doxycycline: Precision Tetracycline Antibiotic for Resear...

  2025-10-23

  Doxycycline stands out as a tetracycline antibiotic and broad-spectrum metalloproteinase inhibitor, enabling targeted experimental workflows in cancer and vascular research. This guide explores optimized protocols, advanced delivery strategies, and troubleshooting insights to maximize Doxycycline’s impact, especially in challenging models like abdominal aortic aneurysm (AAA) and cancer cell proliferation.

• Doxycycline in Precision Research: Mechanistic Advances a...

  2025-10-22

  Doxycycline, a broad-spectrum tetracycline antibiotic and potent metalloproteinase inhibitor, is redefining translational research in cancer and vascular biology through its multifaceted mechanisms and integration into advanced delivery systems. This thought-leadership article synthesizes recent mechanistic discoveries, experimental validation, and strategic guidance for translational researchers, with a special focus on precision drug delivery in complex disease models such as abdominal aortic aneurysm (AAA). By contextualizing the scientific rationale, competitive research landscape, and translational outlook, we illuminate how Doxycycline—particularly when deployed as a research-grade compound—can catalyze next-generation breakthroughs in both laboratory and clinical settings.

• Triptolide: Precision Inhibitor for Cancer and Immunology...

  2025-10-21

  Triptolide (PG490) empowers researchers with nanomolar-potency, mechanistic specificity as an IL-2/MMP-3/MMP7/MMP19 and NF-κB transcription inhibitor, enabling unparalleled control over genome activation, cancer invasion, and immune modulation. From dissecting early pluripotency in Xenopus embryos to inhibiting ovarian cancer metastasis and protecting cartilage in arthritis models, Triptolide’s versatility and reproducibility set it apart as an essential tool in advanced research workflows.

156 records 11/11 page Previous First page 上5页 11